This Group of patients for BetonMace are very sick, unlike past trials ! Mace events could occur much quicker ... lead drug apabetalone (RVX-208) for use in high-risk patients with coronary artery disease (CAD) and type 2 diabetes mellitus (DM). The primary outcome measure will assess the effect of apabetalone on time to first occurrence of Major Adverse Cardiovascular Events (MACE) in high-risk type 2 DM patients with CAD. In the primary outcome measure, MACE is narrowly defined as a single composite endpoint of cardiovascular death, or non-fatal myocardial infarction (MI), or stroke.

Hand picking a narrowly defined group of participants surely must positively lean phase3 results in our favour .

Stock (just my two pennies)